The average EPS estimate for Flex Pharma, Inc. (NASDAQ:FLKS) for the three months ending 2016-12-31 is given as $-0.85.
You find that 7 days ago, the average EPS estimate on the stock was $-0.85, while for the 30 days ago the average EPS estimate stood at $-0.85.
If you look back further, you see that the average EPS estimate for Flex Pharma, Inc. (NASDAQ:FLKS) 60 days ago was given as -0.85, while EPS estimate 90 days ago was quoted at $-0.85.
The change in the stock’s EPS estimate over the last 7 days works out to 0%.
EPS estimate revisions
Over the last 7 days, EPS estimates for Flex Pharma, Inc. (NASDAQ:FLKS) have been revised up 0 times. In the same period, the EPS estimate has been revised down 0 times.
In the last 30 days, the stock has had its EPS estimate revised up 0 and it has been revised up 0 times over the last 60 days.
Up revisions in the last 90 days are 0 and up revisions in the last 120 days are 0.
But for the last 18 days, the company has seen its EPS revised up 0 times, offset by 1 down revisions in the same period.
The down revisions of EPS in last 30, 60, 90 and 120 days were 3, 3, 2 and 2.
What About EPS Surprises
Analysts predicted EPS of $-0.85 for Flex Pharma, Inc. (NASDAQ:FLKS) for the period ended 2. But the company ended up posting actual EPS of $-0.71 on 2016-08-03. The EPS estimate cited was worked out based on 4 estimates that analysts had issued on the stock.
Therefore, Flex Pharma, Inc. (NASDAQ:FLKS) posted EPS surprise of $-0.01 per share in dollar terms, which works out to -1.43%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.23.
Quarterly Sales Estimates
For the fiscal year 2016, the mean and median annual sales estimates for the company are given as $0.266 and $0.24. The estimates are based on the projections of 3 analysts.
So far, the highest annual sales estimate for Flex Pharma, Inc. (NASDAQ:FLKS) stands at$0.5. That compares with the lowest annual sales estimate of $0.06. Calculating the standard deviation of the extreme annual sales estimates leads you to 0.221%.
Annual sales estimate adjustments
In the last 7 days, 3 analysts have raised their annual sales estimates for the company. But over the same period, 3 analysts have trimmed their annual sales estimates.
With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to 0%.
Over the last one month, though, 3 analysts moved to raise their sales estimates for Flex Pharma, Inc. (NASDAQ:FLKS). That compares with 3 analysts who cut their sales estimate for the company in the same period. That leads you to 1.14% as the mean sales estimate change over the last one month.
If you look back further, you see that over the last three months, 3 analysts have moved raise their sales estimates Flex Pharma, Inc. (NASDAQ:FLKS). That offset by 3 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of -25.07% over a period of three months.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...